Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175) [ID620]

Anticipated publication date:

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)
 
Status
In development
Anticipated publication date
December 2014
Process
MTA
Topic area
  • Cancer
  • Respiratory

Provisional Schedule

Closing date for invited submissions / evidence submission: 9 July 2013
1st appraisal committee meeting: 07 January 2013
2nd appraisal committee meeting: 05 March 2014
3rd appraisal committee meeting: 08 July 2014

Project Team

Technical Lead: Martyn Burke
Communications manager: Alice Law
Project manager:

Nicole Fisher

Consultees

Manufacturers/sponsors
  • AstraZeneca (gefitinib)
  • Roche Products (erlotinib)
Patient/carer groups
  • Roy Castle Lung Cancer Foundation
Professional groups
  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)
  • Cancer Research UK
  • National Lung Cancer Forum for Nurses
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
Others
  • Department of Health
  • Welsh Government

Commentators

General
  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Health Improvement Scotland
Comparator manufacturers
  • Accord Healthcare Ltd (docetaxel) (Confidentiality agreement not signed, not participating)
  • Actavis UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Hospira UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Medac UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Sandoz (docetaxel) (Confidentiality agreement not signed, not participating)
  • Sanofi (docetaxel) (Confidentiality agreement not signed, not participating)
  • Teva UK (docetaxel) (Confidentiality agreement not signed, not participating)
Relevant research groups
  • British Thoracic Oncology Group
Assessment Group
  • Liverpool Reviews and Implementation Group (LRIG)
  • National Institute for Health Research Health Technology Assessment Programme
Associated guideline groups
  • National Collaborating Centre for Cancer
Associated public health groups
  • None

Timeline

Key events during the development of the guidance

Date
Update
11 April 2014

An error has recently been identified in the economic model used to inform the Appraisal Committee’s decision making. This may or may not have a material effect on the Committee’s recommendations detailed in the second Appraisal Consultation Document (ACD), out for consultation.

In light of the above, NICE has taken the decision to stop the consultation on the ACD. An addendum to the Assessment Report explaining the error and presenting the impact on cost-effectiveness results will be prepared. NICE will then consult with consultees and commentators on this addendum, before any further Committee discussion.

The next Committee discussion planned for 7 May 2014 has therefore been cancelled. We are currently arranging the next steps and timelines for this appraisal

Get involved